S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

Affimed Stock Price, News & Analysis (NASDAQ:AFMD)

$0.45
0.00 (0.00%)
(As of 12/4/2023 ET)
Compare
Today's Range
$0.44
$0.47
50-Day Range
$0.32
$0.52
52-Week Range
$0.22
$2.15
Volume
373,125 shs
Average Volume
888,023 shs
Market Capitalization
$67.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Affimed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
1,110.4% Upside
$5.50 Price Target
Short Interest
Healthy
1.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.93mentions of Affimed in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.81) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

173rd out of 952 stocks

Pharmaceutical Preparations Industry

70th out of 434 stocks


AFMD stock logo

About Affimed Stock (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD Stock Price History

AFMD Stock News Headlines

Affimed (NASDAQ:AFMD) Short Interest Update
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
StockNews.com Begins Coverage on Affimed (NASDAQ:AFMD)
Truist Financial Reaffirms Their Buy Rating on Affimed (AFMD)
The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
Recap: Affimed Q3 Earnings
Affimed NV AFMD
Affimed to Participate in Upcoming Investor Conferences
What 6 Analyst Ratings Have To Say About Affimed
Expert Ratings for Affimed
See More Headlines
Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$7.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+1,110.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-90,610,000.00
Net Margins
-638.68%
Pretax Margin
-641.56%

Debt

Sales & Book Value

Annual Sales
$43.58 million
Book Value
$1.31 per share

Miscellaneous

Free Float
143,664,000
Market Cap
$67.86 million
Optionable
Optionable
Beta
2.05
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Adi Hoess M.D. (Age 62)
    Ph.D., CEO, MD & Member of Management Board
    Comp: $818.55k
  • Mr. Angus W. Smith (Age 41)
    CFO & Member of Management Board
    Comp: $673.91k
  • Dr. Wolfgang Fischer (Age 59)
    MD, COO & Member of Management Board
    Comp: $638.55k
  • Ms. Denise Mueller (Age 53)
    Chief Business Officer & Member of Management Board
    Comp: $621.41k
  • Dr. Andreas Harstrick M.D. (Age 62)
    Chief Medical Officer & Member of Management Board
    Comp: $529.27k
  • Dr. Arndt Justus Georg Schottelius M.D. (Age 57)
    Ph.D., Chief Scientific Officer & Member of Management Board
    Comp: $641.77k
  • Prof. Melvyn Little
    Founder & Consultant
  • Mr. Michael Wolf (Age 56)
    Head of Finance & Administration
  • Mr. Alexander Fudukidis
    Head of Investor Relations & Director of Investor Relations
  • Mary Beth Sandin
    Vice President of Marketing & Communications














AFMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Affimed stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AFMD shares.
View AFMD analyst ratings
or view top-rated stocks.

What is Affimed's stock price target for 2024?

8 Wall Street research analysts have issued 1 year price objectives for Affimed's shares. Their AFMD share price targets range from $1.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,110.4% from the stock's current price.
View analysts price targets for AFMD
or view top-rated stocks among Wall Street analysts.

How have AFMD shares performed in 2023?

Affimed's stock was trading at $1.24 on January 1st, 2023. Since then, AFMD shares have decreased by 63.4% and is now trading at $0.4544.
View the best growth stocks for 2023 here
.

Are investors shorting Affimed?

Affimed saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,640,000 shares, a drop of 24.1% from the October 31st total of 2,160,000 shares. Based on an average trading volume of 562,700 shares, the days-to-cover ratio is presently 2.9 days.
View Affimed's Short Interest
.

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AFMD earnings forecast
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 104.40% and a negative net margin of 638.68%. During the same quarter in the prior year, the firm earned ($0.08) EPS.

What other stocks do shareholders of Affimed own?
Who are Affimed's major shareholders?

Affimed's stock is owned by many different retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (5.51%), Acadian Asset Management LLC (0.07%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AFMD) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -